CAMBRIDGE, Mass., May 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022.
Event: H.C. Wainwright Global Investment Conference
Date / Time: Monday, May 23rd – Thursday, May 26th, 2022, on demand
Format: Virtual Presentation
Event: Jefferies Healthcare Conference
Date / Time: Thursday, June 9th, 2022, at 4:30pm ET
Format: Live Fireside Chat
A live webcast will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentations.
Management will also be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Theseus management team should contact their H.C. Wainwright or Jefferies representatives.
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.
Amy Jobe, Ph.D.
Stern Investor Relations
SOURCE Theseus Pharmaceuticals